https://pharminent.com/gsk-tesaro-claim-denied-in-jemperli-lawsuit-with-anaptysbio/ 2026-04-27T12:42:25Z Pharminent en GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio 2026-04-27T11:22:22Z Blog https://pharminent.com/rejuvenate-crowdfunds-development-of-gene-therapy-for-aging-chronic-diseases/ 2026-04-27T12:32:27Z Pharminent en Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases 2026-04-27T11:06:10Z Blog https://pharminent.com/jj-puts-blockbuster-blood-thinner-xarelto-on-trumprx/ 2026-04-27T12:32:28Z Pharminent en J&J puts blockbuster blood thinner Xarelto on TrumpRx 2026-04-27T10:58:37Z Blog https://pharminent.com/eli-lilly-acquires-ajax-therapeutics-for-first-in-class-jak2-inhibitor-in-myelofibrosis/ 2026-04-27T12:02:15Z Pharminent en Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis 2026-04-27T10:45:00Z Blog https://pharminent.com/novartis-secures-pair-of-regulatory-wins-for-skin-disease-and-malaria-treatments-2/ 2026-04-27T12:32:29Z Pharminent en Novartis secures pair of regulatory wins for skin disease and malaria treatments 2026-04-27T10:29:48Z Blog https://pharminent.com/new-nihr-funded-trc-for-parkinsons-disease/ 2026-04-27T12:32:30Z Pharminent en New NIHR-funded TRC for Parkinson's disease 2026-04-27T10:08:15Z Blog https://pharminent.com/lilly-falls-on-slower-start-for-foundayo-versus-wegovy/ 2026-04-27T12:32:31Z Pharminent en Lilly falls on slower start for Foundayo versus Wegovy 2026-04-27T10:06:31Z Blog https://pharminent.com/uk-biotech-could-be-bound-for-recovery-bia-report-reveals/ 2026-04-27T12:32:31Z Pharminent en UK biotech could be bound for recovery, BIA report reveals 2026-04-27T09:55:36Z Blog https://pharminent.com/uk-medicines-regulator-grants-marketing-authorisation-to-enflonsia-for-rsv-prevention/ 2026-04-27T12:32:32Z Pharminent en UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention 2026-04-27T09:39:40Z Blog https://pharminent.com/sun-pharma-to-acquire-organon-for-11-75bn-2/ 2026-04-27T12:32:32Z Pharminent en Sun Pharma to acquire Organon for $11.75bn 2026-04-27T09:26:02Z Blog https://pharminent.com/sun-sets-out-11-75bn-takeover-play-for-organon/ 2026-04-27T12:32:33Z Pharminent en Sun sets out $11.75bn takeover play for Organon 2026-04-27T09:10:09Z Blog https://pharminent.com/gene-therapy-leaders-aim-to-help-more-baby-kjs-with-novel-regulatory-models/ 2026-04-27T12:32:33Z Pharminent en Gene therapy leaders aim to help more Baby KJs with novel regulatory models 2026-04-27T04:03:00Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-april-25-2026/ 2026-04-25T23:45:27Z Pharminent en Week in Review • INTELLIGENCE BRIEF • April 25, 2026 2026-04-25T23:45:24Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-april-24-2026/ 2026-04-25T21:29:27Z Pharminent en GLP-1 Competitive Market Digest • Weekly • April 24, 2026 2026-04-25T21:27:29Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-april-24-2026/ 2026-04-25T20:27:32Z Pharminent en Oncology Intelligence Digest • April 24, 2026 2026-04-25T20:27:29Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-april-22-2026/ 2026-04-25T20:24:47Z Pharminent en Manufacturing Intelligence • Weekly Digest • April 22, 2026 2026-04-25T20:24:43Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-april-22-2026/ 2026-04-25T20:22:59Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • April 22, 2026 2026-04-25T20:22:56Z Blog